UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000008099
Receipt number R000009524
Scientific Title A double-blind, controlled trial to evaluate the efficacy and safety of vitamin K1 ointment for cetuximab and Panitumumab-induced acneiform eruption
Date of disclosure of the study information 2012/06/11
Last modified on 2015/07/17 10:55:49

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A double-blind, controlled trial to evaluate the efficacy and safety of vitamin K1 ointment for cetuximab and Panitumumab-induced acneiform eruption

Acronym

Topical VitK1 for Cmab and Pmab-induced acneiform

Scientific Title

A double-blind, controlled trial to evaluate the efficacy and safety of vitamin K1 ointment for cetuximab and Panitumumab-induced acneiform eruption

Scientific Title:Acronym

Topical VitK1 for Cmab and Pmab-induced acneiform

Region

Japan


Condition

Condition

colorectal cancer

Classification by specialty

Gastroenterology Dermatology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Evaluate efficacy and safety of Vitamin K1 ointment for cetuximab-induced acneiform eruption.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

The number of acneiform eruptions of right and left lesions(face, neck, or chest) of the same patient before and after treatment

Key secondary outcomes

Evaluate for acneiform eruption by using CTCAE v4.0 and MASCC scale, safety


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

NO

Dynamic allocation

NO

Institution consideration


Blocking

NO

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

0.1% vitamin K1 ointment twice daily

Interventions/Control_2

Placebo ointment twice daily

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1.Age: 20 or older
2.Cetuximab or Panitumumab-induced acneiform eruption on face, neck or chest
3.Written informed consent

Key exclusion criteria

1.Currently treated with vitamin K analog or antagonist
2.Pregnancy or brestfeeding
3.Not eligible judged by physicians

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hironobu Hashimoto

Organization

National Cancer Center Hoapital

Division name

Pharmacy division

Zip code


Address

5-1-1, Tsukiji, Chuo-ku, Tokyo

TEL

03-3542-2511

Email

hhashimo@ncc.go.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hironobu Hashimoto

Organization

National Cancer Center Hoapital

Division name

Pharmacy division

Zip code


Address

5-1-1, Tsukiji, Chuo-ku, Tokyo

TEL

03-3542-2511

Homepage URL


Email

hhashimo@ncc.go.jp


Sponsor or person

Institute

National Cancer Center Hospital Pharmacy division

Institute

Department

Personal name



Funding Source

Organization

National Cancer Center Hospital Pharmacy division

Organization

Division

Category of Funding Organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

国立がん研究センター中央病院


Other administrative information

Date of disclosure of the study information

2012 Year 06 Month 11 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 05 Month 24 Day

Date of IRB


Anticipated trial start date

2012 Year 06 Month 01 Day

Last follow-up date

2015 Year 06 Month 01 Day

Date of closure to data entry

2015 Year 09 Month 01 Day

Date trial data considered complete

2015 Year 12 Month 01 Day

Date analysis concluded

2016 Year 03 Month 01 Day


Other

Other related information



Management information

Registered date

2012 Year 06 Month 04 Day

Last modified on

2015 Year 07 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009524


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name